Synthetic OpenEMR / FHIR-style transport
Annotated oncology EHR example
Synthetic annotated oncology EHR and claims transport with source trace, treatment-failure signals, ECOG, and data-quality flags.
Patient token
SYN-ONC-0007
Cancer
Malignant neoplasm of upper lobe, right bronchus or lung
Stage / biomarker
Stage IVB; EGFR exon 19 deletion
Linkage confidence
0.94
Longitudinal record
Timeline
DiagnosisStage IVB
Ambulatorynew lung mass workup
Creatinine0.9 mg/dL
Start LOT 1osimertinib
ECOG Performance Status1
Ambulatorysystemic therapy start
CEA21.4 ng/mL
Emergencydyspnea and pleural effusion
imaging-summaryprogressive disease
Stop therapyradiographic progression / non-response
ECOG Performance Status2
Candidate failure dateprobable treatment failure / non-response
Start LOT 2carboplatin + pemetrexed + pembrolizumab
Constructed endpoint
Treatment failure evidence
Classification: probable treatment failure / non-response; certainty: moderate; candidate date: 2024-08-05.
- medrx-1MedicationRequest stopped for progression
- medrx-2New line of therapy started within 7 days
- img-1Imaging summary says progressive disease
- ecog-2ECOG worsened from 1 to 2
- enc-3Emergency encounter for dyspnea and pleural effusion
Baseline and follow-up
Patient context
| Age at index | 66 |
|---|---|
| Sex | female |
| Race / ethnicity | Black or African American; Not Hispanic or Latino |
| Region | US-South |
| Payer type | commercial |
| Subscriber / member | sub_44fd19 / mem_772ac1 |
Treatment and observations
| LOT | Drug | Start | Stop | Status |
|---|---|---|---|---|
| 1 | osimertinib | 2024-02-09 | 2024-08-05 | radiographic progression / non-response |
| 2 | carboplatin + pemetrexed + pembrolizumab | 2024-08-12 | active | active |
| Date | Observation | LOINC | Value | RWE use |
|---|---|---|---|---|
| 2024-02-05 | Creatinine | 2160-0 | 0.9 | Baseline renal covariate. |
| 2024-07-15 | CEA | 2039-6 | 21.4 | Tumor-marker progression support. |
| 2024-02-09 | ECOG Performance Status | 89247-1 | 1 | Baseline functional-status covariate. |
| 2024-08-05 | ECOG Performance Status | 89247-1 | 2 | Clinical deterioration and endpoint-support signal. |
| 2024-08-01 | imaging-summary | progressive disease | Clinical response component; not RECIST-confirmed unless source report is available. |
Source trace
| Derived field | Trace |
|---|---|
| line of therapy | MedicationRequest sequence and stop/start dates |
| treatment failure non response | Medication status reason, imaging summary, ECOG change, next-line therapy, and ED utilization |
| claims | Payer extract line-level claims linked to encounter IDs |
| ecog | Structured observation using LOINC 89247-1 |
Data quality flags
| Flag | Severity | Affects |
|---|---|---|
| synthetic_record | info | all fields |
| date_shifted | info | calendar-time interpretation |
| imaging_not_recist_confirmed | medium | treatment_failure_non_response |
| claims_ehr_linkage_probabilistic | medium | claims_linkage |
| oral_adherence_unobserved | medium | osimertinib exposure duration |
Claims linkage
| Date | Setting | Claim | Encounter |
|---|---|---|---|
| 2024-02-09 | outpatient | claim_77aa | enc-2 |
| 2024-07-21 | emergency | claim_91fd | enc-3 |
JSON transport
{
"transport_meta": {
"schema": "rwednesdays.synthetic_oncology_ehr.v0.1",
"style": "OpenEMR/FHIR-R4-like longitudinal patient bundle",
"synthetic": true,
"date_shifted": true,
"contains_phi": false,
"generated_at": "2026-06-18T12:00:00-04:00",
"license_note": "Synthetic example for methods education only; not medical advice and not patient data."
},
"patient": {
"synthetic_patient_id": "SYN-ONC-0007",
"pseudonymized_ids": {
"ehr_patient_token": "ehrtok_9b7a2d",
"claims_patient_token": "clmtok_51fd90",
"linkage_confidence": 0.94
},
"demographics": {
"age_at_index": 66,
"sex": "female",
"race": "Black or African American",
"ethnicity": "Not Hispanic or Latino",
"region": "US-South"
},
"_rwe": "Cohort eligibility, baseline covariates, subgroup checks, and linkage denominator."
},
"diagnoses": [
{
"id": "cond-1",
"resource_type": "Condition",
"code": {
"system": "ICD-10-CM",
"code": "C34.11",
"display": "Malignant neoplasm of upper lobe, right bronchus or lung"
},
"clinical_status": "active",
"verification_status": "confirmed",
"onset_date": "2024-01-18",
"stage_at_diagnosis": "Stage IVB",
"biomarkers": [
{
"name": "EGFR exon 19 deletion",
"result": "positive",
"date": "2024-02-02"
}
],
"_rwe": "Incident cancer diagnosis, disease site, stage, and molecular eligibility subgroup."
}
],
"encounters": [
{
"id": "enc-1",
"resource_type": "Encounter",
"class": "ambulatory",
"date": "2024-01-18",
"provider_type": "oncology",
"reason": "new lung mass workup",
"_rwe": "Care setting and index workup."
},
{
"id": "enc-2",
"resource_type": "Encounter",
"class": "ambulatory",
"date": "2024-02-09",
"provider_type": "medical oncology",
"reason": "systemic therapy start",
"_rwe": "Index date anchor."
},
{
"id": "enc-3",
"resource_type": "Encounter",
"class": "emergency",
"date": "2024-07-21",
"reason": "dyspnea and pleural effusion",
"_rwe": "Acute utilization and possible progression signal."
}
],
"medications": [
{
"id": "medrx-1",
"resource_type": "MedicationRequest",
"drug": "osimertinib",
"rxnorm": "1723758",
"intent": "order",
"status": "stopped",
"start_date": "2024-02-09",
"stop_date": "2024-08-05",
"dose": "80 mg oral daily",
"status_reason": "radiographic progression / non-response",
"line_of_therapy": 1,
"_rwe": "Exposure, line-of-therapy start/stop, and treatment discontinuation signal."
},
{
"id": "medrx-2",
"resource_type": "MedicationRequest",
"drug": "carboplatin + pemetrexed + pembrolizumab",
"status": "active",
"start_date": "2024-08-12",
"line_of_therapy": 2,
"_rwe": "Post-failure regimen switch and next-line therapy."
}
],
"observations": [
{
"id": "lab-1",
"resource_type": "Observation",
"category": "laboratory",
"loinc": "2160-0",
"name": "Creatinine",
"date": "2024-02-05",
"value": 0.9,
"unit": "mg/dL",
"_rwe": "Baseline renal covariate."
},
{
"id": "lab-2",
"resource_type": "Observation",
"category": "laboratory",
"loinc": "2039-6",
"name": "CEA",
"date": "2024-07-15",
"value": 21.4,
"unit": "ng/mL",
"trend": "rising from 8.2",
"_rwe": "Tumor-marker progression support."
},
{
"id": "ecog-1",
"resource_type": "Observation",
"category": "survey",
"loinc": "89247-1",
"name": "ECOG Performance Status",
"date": "2024-02-09",
"valueInteger": 1,
"_rwe": "Baseline functional-status covariate."
},
{
"id": "ecog-2",
"resource_type": "Observation",
"category": "survey",
"loinc": "89247-1",
"name": "ECOG Performance Status",
"date": "2024-08-05",
"valueInteger": 2,
"_rwe": "Clinical deterioration and endpoint-support signal."
},
{
"id": "img-1",
"resource_type": "Observation",
"category": "imaging-summary",
"date": "2024-08-01",
"valueCode": "progressive disease",
"source": "oncology note abstraction",
"_rwe": "Clinical response component; not RECIST-confirmed unless source report is available."
}
],
"treatment_failure_non_response": {
"constructed_endpoint": true,
"candidate_failure_date": "2024-08-05",
"classification": "probable treatment failure / non-response",
"certainty": "moderate",
"signals": [
{
"source_id": "medrx-1",
"signal": "MedicationRequest stopped for progression"
},
{
"source_id": "medrx-2",
"signal": "New line of therapy started within 7 days"
},
{
"source_id": "img-1",
"signal": "Imaging summary says progressive disease"
},
{
"source_id": "ecog-2",
"signal": "ECOG worsened from 1 to 2"
},
{
"source_id": "enc-3",
"signal": "Emergency encounter for dyspnea and pleural effusion"
}
],
"_rwe": "Composite endpoint combining clinical response evidence, treatment-pattern proxy, and intercurrent-event handling."
},
"claims_linkage": {
"payer_type": "commercial",
"subscriber_id_hash": "sub_44fd19",
"member_id_hash": "mem_772ac1",
"enrollment": [
{
"start": "2023-12-01",
"end": "2024-12-31",
"medical": true,
"pharmacy": true
}
],
"claim_refs": [
{
"claim_id_hash": "claim_77aa",
"date": "2024-02-09",
"setting": "outpatient",
"hcpcs": "99215",
"linked_encounter": "enc-2"
},
{
"claim_id_hash": "claim_91fd",
"date": "2024-07-21",
"setting": "emergency",
"revenue_center": "0450",
"linked_encounter": "enc-3"
}
],
"_rwe": "Coverage continuity, utilization capture, EHR-claims concordance, and subscriber/member identifier separation."
},
"provenance": {
"source_systems": [
"synthetic OpenEMR-like EHR",
"synthetic adjudicated claims"
],
"mapping_version": "oncology-ehr-rwe-map-0.1",
"source_trace": {
"line_of_therapy": "MedicationRequest sequence and stop/start dates",
"treatment_failure_non_response": "Medication status reason, imaging summary, ECOG change, next-line therapy, and ED utilization",
"claims": "Payer extract line-level claims linked to encounter IDs",
"ecog": "Structured observation using LOINC 89247-1"
}
},
"data_quality_flags": [
{
"flag": "synthetic_record",
"severity": "info",
"affects": "all fields"
},
{
"flag": "date_shifted",
"severity": "info",
"affects": "calendar-time interpretation"
},
{
"flag": "imaging_not_recist_confirmed",
"severity": "medium",
"affects": "treatment_failure_non_response"
},
{
"flag": "claims_ehr_linkage_probabilistic",
"severity": "medium",
"confidence": 0.94,
"affects": "claims_linkage"
},
{
"flag": "oral_adherence_unobserved",
"severity": "medium",
"affects": "osimertinib exposure duration"
}
],
"source_references": [
{
"label": "OpenEMR FHIR API documentation",
"url": "https://github.com/openemr/openemr/blob/master/Documentation/api/FHIR_API.md"
},
{
"label": "HL7 FHIR R4 Encounter",
"url": "https://hl7.org/fhir/R4/encounter.html"
},
{
"label": "HL7 FHIR R4 Condition",
"url": "https://hl7.org/fhir/R4/condition.html"
},
{
"label": "HL7 FHIR R4 MedicationRequest",
"url": "https://hl7.org/fhir/R4/medicationrequest.html"
},
{
"label": "HL7 FHIR R4 Observation",
"url": "https://hl7.org/fhir/R4/observation.html"
},
{
"label": "mCODE ECOG Performance Status",
"url": "https://build.fhir.org/ig/HL7/fhir-mCODE-ig/StructureDefinition-mcode-ecog-performance-status.html"
},
{
"label": "FDA Real-World Data guidance",
"url": "https://www.fda.gov/media/152503/download"
}
]
}